NCT03669718
|
Phase II |
Cemiplimab + ISA101b
Cemiplimab
|
A Randomized Phase 2 Study of Cemiplimab +/- ISA101b in HPV16-Positive OPC |
Recruiting |
NCT03477864
|
Phase I |
Ipilimumab
Ipilimumab + REGN2810
Cemiplimab
|
Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer |
Recruiting |
NCT03565783
|
Phase II |
Cemiplimab
|
Study of REGN2810 Prior to Surgery in Patients With Advanced-Stage, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck |
Recruiting |
NCT03690869
|
Phase Ib/II |
Cemiplimab
|
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma |
Recruiting |
NCT03430063
|
Phase II |
Ipilimumab + REGN2810
Cemiplimab
|
A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer |
Recruiting |
NCT02651662
|
Phase I |
Cemiplimab
REGN1979 + REGN2810
|
Study of REGN2810 and REGN1979 in Patients With Lymphoma |
Recruiting |
NCT03409614
|
Phase III |
Ipilimumab + REGN2810
Cemiplimab
|
REGN2810 (Anti-PD-1 Antibody), Ipilimumab (Anti-CTLA-4 Antibody), and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer |
Recruiting |
NCT03257267
|
Phase III |
Irinotecan
Gemcitabine
Vinorelbine
Pemetrexed
Cemiplimab
Topotecan
|
Study of REGN2810 in Adults With Cervical Cancer |
Recruiting |
NCT03132636
|
Phase II |
Cemiplimab
|
PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy |
Recruiting |
NCT02760498
|
Phase II |
Cemiplimab
|
Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma |
Recruiting |
NCT02383212
|
Phase I |
Cemiplimab + Carboplatin + Docetaxel
Cemiplimab + Carboplatin + Pemetrexed
REGN2810 + GM-CSF + Cyclophosphamide
Cemiplimab + Cyclophosphamide
Cemiplimab
Cemiplimab + Carboplatin + Paclitaxel
Cemiplimab + Docetaxel
|
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies |
Active, not recruiting |